Treatment of proliferative XXXX : a slowly changing landscape.

@entity1 @entity8 @entity137 @entity66 @entity500 @entity786 @entity1988 @entity288 @entity281 @entity205 @entity618 @entity2670 @entity6051 @entity454
Proliferative @entity1988 is the most severe form of @entity1988 . Outcomes of this disease are affected by ethnicity, clinical characteristics, irreversible damage on renal biopsy, initial response to treatment and future disease course (for example, the occurrence of @entity8 ). Initial intensive (induction) treatment of proliferative @entity1988 is aimed at achieving remission, but optimal duration and intensity are not well defined. A combination of intravenous @entity786 and @entity288 have been shown to decrease the risk of @entity454 , but are associated with substantial acute toxic effects (such as @entity281 ) and chronic toxic effects (such as @entity2670 ). In white populations, low-dose @entity786 is a reasonable alternative to high-dose @entity786 as it is similarly effective and associated with less @entity137 . @entity6051 mofetil is as effective as high-dose intravenous @entity786 in terms of inducing remission and similar in terms of safety. Although most @entity1 respond to induction treatment, remission is often only achieved after @entity1 are switched to maintenance treatment. As maintenance treatment, @entity618 is superior to @entity500 and @entity500 is similarly effective to @entity205 in terms of prevention or reducing the risk of relapse. Rituximab should be reserved for @entity1 with @entity66 . Treatment of @entity1988 should be individually tailored to @entity1 , with more aggressive therapy reserved for @entity1 at high risk of @entity8 and progression of @entity8 .
